Benitec Biopharma (NASDAQ:BNTC – Free Report) had its price objective raised by JMP Securities from $10.00 to $16.00 in a research note issued to investors on Monday, Benzinga reports. They currently have a market outperform rating on the biotechnology company’s stock.
Benitec Biopharma Trading Up 2.7 %
Benitec Biopharma stock opened at $6.90 on Monday. The business’s fifty day moving average is $5.06 and its two-hundred day moving average is $3.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.62 and a quick ratio of 3.62. Benitec Biopharma has a 52 week low of $1.86 and a 52 week high of $9.01.
Benitec Biopharma (NASDAQ:BNTC – Get Free Report) last released its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported ($2.64) EPS for the quarter.
Institutional Trading of Benitec Biopharma
Benitec Biopharma Company Profile
Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.
See Also
- Five stocks we like better than Benitec Biopharma
- Where to Find Earnings Call Transcripts
- Hasbro’s Management Made All the Right Calls This Quarter
- Most Volatile Stocks, What Investors Need to Know
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Benitec Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Benitec Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.